Literature DB >> 26949649

Optical coherence tomography characteristics of responses to intravitreal bevacizumab in idiopathic choroidal neovascularization.

Syed Nasir Ali Shah1, Qian-Yan Kang1, Xiao-Juan Fan1, Yue-Ming Sun1.   

Abstract

AIM: To investigate factors associated with responses to intravitreal bevacizumab (IVB) in naive idiopathic choroidal neovascularization (iCNV) by high domain optical coherence tomography (OCT).
METHODS: We retrospectively reviewed clinical data of 40 eyes of iCNV patients who received a single or multiple IVB on an as-needed basis (1.25 mg/0.05 mL). One month after the first injection, subretinal fluid (SRF) volume was evaluated and the eyes were divided into 3 groups based on responses to IVB. Good, moderate, and poor responses were defined as 61%-99%, 30%-60%, and <30% resolution of SRF on OCT after IVB in iCNV, respectively. OCT findings were analyzed to find factors associated with difference in response levels. Comparisons were made using Wilcoxon's matched-pairs signed-rank test, the Mann-Whitney U test for means with continuous data and Fisher's exact test for categorical data.
RESULTS: The mean number of IVB was 1.28±1.50 and mean follow up time was 3.60±1.20mo. At postoperative 1mo, there were 8 (20%) eyes in good response, 20 (50%) in moderate response and 12 (30%) eyes in poor response group and at last visit there were 28 good responders (70%), 8 (20%) moderate responders and 4 (10%) poor responders. Statistically significant difference was detected between good responders and non good responders in choroidal neovessels thickness (P=0.029), SRF height (P=0.049) and SRF volume (P=0.031) at post treatment 1mo.
CONCLUSION: OCT is a valuable diagnostic tool. Decrease in choroidal neovessels thickness, SRF height and volume predicts favorable response of iCNV to IVB therapy.

Entities:  

Keywords:  bevacizumab; idiopathic choroidal neovascularisation; optical coherence tomography; subretinal fluid

Year:  2016        PMID: 26949649      PMCID: PMC4761741          DOI: 10.18240/ijo.2016.02.17

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  21 in total

1.  Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.

Authors:  Han Zhang; Zhe-Li Liu; Peng Sun; Feng Gu
Journal:  Am J Ophthalmol       Date:  2011-10-06       Impact factor: 5.258

2.  Intravitreal bevacizumab for idiopathic choroidal neovascularization.

Authors:  Mehmet Cakir; Osman Cekiç; O Faruk Yilmaz
Journal:  J AAPOS       Date:  2009-03-14       Impact factor: 1.220

3.  Idiopathic focal subretinal neovascularization.

Authors:  G W Cleasby
Journal:  Am J Ophthalmol       Date:  1976-05       Impact factor: 5.258

4.  Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.

Authors:  Maiko Inoue; Kazuaki Kadonosono; Yoichiro Watanabe; Shimpei Sato; Satoshi Kobayashi; Shin Yamane; Rieko Ito; Akira Arakawa
Journal:  Retina       Date:  2010-05       Impact factor: 4.256

5.  Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy.

Authors:  Hyesun Kim; Kahyun Lee; Christopher Seungkyu Lee; Suk Ho Byeon; Sung Chul Lee
Journal:  Retina       Date:  2015-03       Impact factor: 4.256

6.  Natural history of retinal pigment epithelial detachments in age-related macular degeneration.

Authors:  L S Poliner; R J Olk; D Burgess; M E Gordon
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

7.  Etiology of choroidal neovascularization in young patients.

Authors:  S Y Cohen; A Laroche; Y Leguen; G Soubrane; G J Coscas
Journal:  Ophthalmology       Date:  1996-08       Impact factor: 12.079

8.  Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration.

Authors:  Yeo Jue Byun; Sung Jun Lee; Hyoung Jun Koh
Journal:  Jpn J Ophthalmol       Date:  2010-12-30       Impact factor: 2.447

9.  Effects on choroidal neovascularization after anti-VEGF Upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography.

Authors:  Carsten Framme; Georgios Panagakis; Reginald Birngruber
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-29       Impact factor: 4.799

10.  Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.

Authors:  Tim U Krohne; Nicole Eter; Frank G Holz; Carsten H Meyer
Journal:  Am J Ophthalmol       Date:  2008-07-17       Impact factor: 5.258

View more
  3 in total

1.  Effects of VEGF levels on anti-VEGF therapy for patients with idiopathic choroidal neovascularization.

Authors:  Xiaojuan Fan; Ning Gao; Jingming Li; Jianqin Lei; Qianyan Kang
Journal:  Mol Cell Biochem       Date:  2017-09-07       Impact factor: 3.396

2.  Macular thickness in healthy Saudi adults. A spectral-domain optical coherence tomography study.

Authors:  Waseem M Al-Zamil; Fahad M Al-Zwaidi; Sanaa A Yassin
Journal:  Saudi Med J       Date:  2017-01       Impact factor: 1.484

3.  Spectral domain-optical coherence tomography retinal biomarkers in choroidal neovascularization of multifocal choroiditis, myopic choroidal neovascularization, and idiopathic choroidal neovascularization.

Authors:  Rui Gao; Jingxue Ma; Zhengwei Zhang; Qingli Shang; Jialiang Duan
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.